JCR Pharmaceuticals

JCR Pharmaceuticals

Verified
JCR has been proactively engaged in research and development (R&D) of biopharmaceuticals based on recombinant DNA technologies

Launch date
Employees
Market cap
JPY295.3b
Net debt
(JPY7.4b)
Firm valuation
$2.1b (Public information from Aug 2022)
Hyogo-Ku Japan (HQ)
Deals in current and previous year:

Financials

Edit
Revenues, earnings & profits over time
EUR2016201720182019202020212022E
Revenues-127m144m162m173m211m348m
% growth--14 %12 %7 %21 %65 %
EBITDA-26.7m36.2m44.2m32.7m71.1m177m
% EBITDA margin-21 %25 %27 %19 %34 %51 %
Profit-13m21.5m26m18.7m48.2m108m
% profit margin-10 %15 %16 %11 %23 %31 %
EV / revenue-4.3x9.0x8.5x11.6x14.5x5.0x
EV / EBITDA-20.2x36.0x31.3x61.6x42.8x9.8x
R&D budget33m31m34m49m---
R&D % of revenue-24 %24 %30 %---

Source: Company fillings or news article

  • Edit
DateInvestorsAmountRound
N/ASeed
N/AN/AIPO
Total Funding-

Recent News about JCR Pharmaceuticals

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.

Investments by JCR Pharmaceuticals

Edit
ArmaGen Technologies
ACQUISITION by JCR Pharmaceuticals Mar 2020